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OBJECTIVES: To estimate the resources use and associated
direct costs of hospital care for primary stroke patients in
Poland. METHODS: Study design: The prospective, bottom-up,
naturalistic, multicenter cost of illness study. Patients: Primary
stroke patients successively admitted to three hospital centers of
different institution. Data on clinical characteristics (i.e. risk
factors, prestroke status, clinical state on admission and 
discharge) and hospital resources use (i.e. type of ward state,
diagnostic and therapeutic procedures, drugs, specialists’ con-
sultations and other medical professionals work, transport) were
collected. Unit costs for all resources used were calculated using
participating hospitals account systems and other available tariff
tables. Extensive sensitivity analysis was performed using data
on large number of stroke patients hospitalized in over 40 centers
in 2001 and 2002. Values are expressed in zl (1USD = 1.95zl;
1Euro = 2.32 purchasing power parities). RESULTS: One
hundred sixty-four patients were enrolled (mean age:71.4;
man:40.6%). Strokes were diagnosed as ischaemic in 85.8%,
hemorrhagic in 8.02% and unclassiﬁed in 6.17%. Mean hospi-
tal stay was 12.3 days, including 1.4 days on high dependency
ward, 6.9 days on stroke unit and 3.8 days on general ward.
Total cost of hospital service amounted for 5258zl (95%CI:
4880;5663), with one-ﬁfth due to variable costs, i.e. diagnostic
and therapeutic procedures (451zl), drugs (262zl), consultations
(35zl), work costs (241zl) and transport (123zl). CONCLU-
SIONS: The resources use and associated direct cost of hospital
care for primary stroke patients in Poland are substantial,
although ﬁxed costs represent majority of it.
PNL7
COSTS OF STROKE UNIT CARE IN GERMANY
Back T1, Haacke C2, Spottke EA3, Schöffski O4, Dodel R3
1Marburg University, Marburg, Germany; 2University of Marburg;
3Friedrich-Wilhelms-University, Bonn, Germany; 4University of
Erlangen
OBJECTIVES: Stroke imposes a considerable economic burden
on the individual and society. Recently, the concept of an inte-
grated stroke unit has been established in several countries to
improve the outcome of patients. This study evaluates the costs
of acute care of the different cerebrovascular insults on a stroke
unit. METHODS: All patients included were consecutively
admitted to the Department of Neurology, Philipps University
Marburg, with the diagnosis of stroke or transient ischemic
attacks (TIAs) between 1st January and 30th June 2000 (n =
340). Clinical status and course were evaluated by using the
Barthel index and the modiﬁed Rankin scale. Employing a
“bottom-up” approach, we calculated the costs from the per-
spective of the hospital and the third party payer using data from
provider departments and other published sources. RESULTS:
In-patient costs were €3020 (US-$3320), €3480 (US-$3840),
€5080 (US-$5590) for TIA, ischemic stroke (IS) and intracere-
bral hemorrhage (ICH), respectively. Patient sub-groups ranked
in the same order for average length of stay (LOS) at 9.4d for
TIA, 10.2d for IS and 11.9d for ICH. Approximately, 30% of
the hospital costs are due to physician charges and care. Imaging
was 10% and lab investigations were 14% of total costs, inde-
pendent of the diagnosis. Post-acute treatment, including in-
patient rehabilitation, amounted to €9880. In all patients
independent of the diagnosis a considerable clinical improvement
was found at time of discharge. CONCLUSIONS: Care of
patients with cerebrovascular events in a stroke unit causes a
high demand of resources and has a considerable impact on
healthcare expenditure. Therefore, more detailed comparative
investigations are necessary to evaluate the stroke unit concept
for a rationale use of available resources in patients with cere-
brovascular events.
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OBJECTIVES: To estimate the cost-effectiveness of intravenous
recombinant tissue plasminogen activator (rt-PA) therapy for
acute ischemic stroke from the perspective of Taiwan National
Health Insurance system. METHODS: A decision-analytic
model was developed to perform the cost-effectiveness analysis
of rt-PA treatment for acute ischemic stroke. We considered only
costs of hospitalization (initial acute care and recurrence)
because estimates of long-term care in Taiwan are not available.
The estimates of efﬁcacy of rt-PA were based on an updated
Cochrane systematic review of randomized trials of thromboly-
sis. Data on costs, health outcomes, and utilities of disability
were taken from a hospital-based study (360 ﬁrst-ever ischemic
stroke patients), national statistics, and literature-derived values.
Costs per quality-adjusted life-year (QALY) were calculated for
a hypothetical cohort of 1000 eligible patients, with starting age
65 years. RESULTS: The model suggested that over the lifetime
a patient treated with rt-PA (within 3 hours of stroke onset)
gained 0.21 QALYs, at a cost of NT$131,900 (US$4211) per
QALY. CONCLUSIONS: Using rt-PA in treating acute ischemic
stroke in Taiwan is likely to generate health beneﬁts at modest
extra costs.
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OBJECTIVES: From SISYPHE—a case-control study in occupa-
tional health institution in Paris area—we calculated indirect
costs associated to insomnia. METHODS: Number and duration
of work absence, reported retrospectively over the last 2-year
period by a group of insomniac employees and a group of good
sleeper employees, were basic data for the calculation of indirect
costs. We adopted the perspective of the Sickness Fund (SF) for
the private sector and the perspective of the employer (produc-
tivity) for the private and the public sector. The costing was per-
formed combining number and duration of work absence, the
level of incomes of employees in 2000, the annual number of
workdays, the SF rules and employer rules for the coverage of
workdays loss in private sector and the published added value
for the evaluation of loss of productivity. RESULTS: A total of
568 work absence were reported from 313 employees (public +
private sector). Average duration of work absence per employ-
ees were 12.9 days (±2.27) and 10.2 (±2.02) days for insomniac
and good sleeper respectively. Incremental cost associated to
insomnia in the perspective of the SF for employees of private
sector was estimated at 130€ per year for insomniac employee.
The rate of coverage by the SF represents 26% of the total cov-
erage (SF + employers). Incremental loss of productivity associ-
ated to insomnia is estimated at 1419€ per year for insomniac
employee. CONCLUSIONS: Design of SISYPHE allows us to
calculate indirect cost associated to insomnia. We observe SF
accounts only for one quarter of the total coverage. Loss of pro-
ductivity is 10-fold higher compared to SF coverage.
